Skip to main content

Capricor Therapeutics, Inc.

CAPR
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001133869

No open-market purchases or sales by Capricor Therapeutics, Inc. insiders were filed in the last 90 days; 169 institutions reported holding it in 13F filings for Q2 2026, worth $941.6M in total; no superinvestor holds it.

Q3 2022 vs. Q2 2022

How the institutions holding Capricor Therapeutics, Inc. changed between Q2 2022 and Q3 2022.

All holders in Q3 2022All holders in Q2 2022

13F holders of CAPR: Q2 2022 compared with Q3 2022
MeasureQ2 2022Q3 2022Change
Holders2931+2
Shares2.54M2.79M+248.7K (+9.8%)
Value$8.87M$16.8M+$7.88M (+88.8%)

New holders (6)

Institutions that held Capricor Therapeutics, Inc. at the end of Q3 2022 but not at the end of Q2 2022.

Institutions new to CAPR in Q3 2022
InstitutionSharesValue% of portfolio
Millennium Management LLC27,288$164.0K0.00%
Cubist Systematic Strategies, LLC22,955$138.0K0.00%
Jump Financial, LLC22,600$136.0K0.01%
Renaissance Technologies LLC10,200$61.0K0.00%
BNP Paribas Arbitrage, SA100$6000.00%
Wipfli Financial Advisors LLC,4$00.00%

Sold out (4)

Institutions that held Capricor Therapeutics, Inc. at the end of Q2 2022 and filed for Q3 2022 without it.

Institutions that sold out of CAPR in Q3 2022
InstitutionShares, Q2 2022Value, Q2 2022
UBS Group AG29,352$102.0K
Charles Schwab Investment Management Inc14,832$52.0K
Tower Research Capital LLC (TRC)1,684$5.00K
Northwestern Mutual Wealth Management Co500$2.00K